|
[1] RAWLA P, SUNKARA T, MURALIDHARAN P, et al. Update in global trends and aetiology of hepatocellular carcinoma[J].Contemp Oncol(Pozn), 2018, 22(3):141-150.
|
|
[2] WANG Y, DONG Q, ZHANG Q, et al. Overexpression of yesassociated protein contributes to progression and poor prognosis of non-small-cell lung cancer[J]. Cancer Sci, 2010, 101(5):1279-1285.
|
|
[3] XIA Y, CHANG T, WANG Y, et al. YAP promotes ovarian cancer cell tumorigenesis and is indicative of a poor prognosis for ovarian cancer patients[J]. PLoS One, 2014, 9(3):e91770.
|
|
[4] YANG Y, WU QJ, XIE L, et al. Prospective cohort studies of association between family history of liver cancer and risk of liver cancer[J]. Int J Cancer, 2014, 135(7):1605-1614.
|
|
[5] OTA M, SASAKI H. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling[J]. Development, 2008, 135(24):4059-4069.
|
|
[6] ZHAO B, WEI X, LI W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control[J]. Genes Dev, 2007, 21(21):2747-2761.
|
|
[7] HALDER G, JOHNSON RL. Hippo signaling:Growth control and beyond[J]. Development, 2011, 138(1):9-22.
|
|
[8] ZANCONATO F, BATTILANA G, CORDENONSI M, et al. YAP/TAZ as therapeutic targets in cancer[J]. Curr Opin Pharmacol,2016, 29:26-33.
|
|
[9] ZHU C, LI L, ZHAO B. The regulation and function of YAP transcription co-activator[J]. Acta Biochim Biophys Sin(Shanghai), 2015, 47(1):16-28.
|
|
[10] MACIAS MJ, HYVÖNEN M, BARALDI E, et al. Structure of the WW domain of a kinase-associated protein complexed with a proline-rich peptide[J]. Nature, 1996, 382(6592):646-649.
|
|
[11] YAGI R, CHEN LF, SHIGESADA K, et al. A WW domaincontaining yes-associated protein(YAP)is a novel transcriptional co-activator[J]. EMBO J, 1999, 18(9):2551-2562.
|
|
[12] OKA T, REMUE E, MEERSCHAERT K, et al. Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling[J].Biochem J, 2010, 432(3):461-472.
|
|
[13] KOWALIK MA, SALIBA C, PIBIRI M, et al. Yes-associated protein regulation of adapative liver enlargement and hepatocellular carcinoma development in mice[J]. Hepatology,2011, 53(6):2086-2096.
|
|
[14] MOON S, KIM W, KIM S, et al. Phosphorylation by NLK inhibits YAP-14-3-3-interactions and induces its nuclear localization[J]. EMBO Rep, 2017, 18(1):61-71.
|
|
[15] LIU CY, ZHA ZY, ZHOU X, et al. The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase[J]. J Biol Chem, 2010, 285(48):37159-37169.
|
|
[16] HANSEN CG, MOROISHI T, GUAN KL. YAP and TAZ:A nexus for Hippo signaling and beyond[J]. Trends Cell Biol,2015, 25(9):499-513.
|
|
[17] MOROISHI T, HANSEN CG, GUAN KL. The emerging roles of YAP and TAZ in cancer[J]. Nat Rev Cancer, 2015, 15(2):73-79.
|
|
[18] MOYA IM, HALDER G. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine[J]. Nat Rev Mol Cell Biol, 2019, 20(4):211-226.
|
|
[19] GUO LW, SHAO GL, LUO J, et al. YAP regulates the proliferation and modifies the sensitivity to sorafenib in hepatocellular carcinoma cells[J]. Chin J Oncol, 2018, 40(11):818-823.(in Chinese）郭立文，邵国良，罗君，等．YAP调控肝癌细胞增殖活性及对索拉非尼敏感性的影响[J]．中华肿瘤杂志，2018, 40(11):818-823.
|
|
[20] BÖTTCHER K, PINZANI M. Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents[J]. Adv Drug Deliv Rev, 2017, 121:3-8.
|
|
[21] ZAGHARI Z, AZIZIAN J. Synthesis of novelα-amidino carboxylic acids and their use as H-Bond catalysts in strecker reaction[J]. Comb Chem High Throughput Screen, 2018, 21(8):609-614.
|
|
[22] de OLIVEIRA DA SILVA B, RAMOS LF, MORAES K. Molecular interplays in hepatic stellate cells:Apoptosis, senescence,and phenotype reversion as cellular connections that modulate liver fibrosis[J]. Cell Biol Int, 2017, 41(9):946-959.
|
|
[23] DUPONT S, MORSUT L, ARAGONA M, et al. Role of YAP/TAZ in mechanotransduction[J]. Nature, 2011, 474(7350):179-183.
|
|
[24] MANNAERTS I, LEITE SB, VERHULST S, et al. The Hippo pathway effector YAP controls mouse hepatic stellate cell activation[J]. J Hepatol, 2015, 63(3):679-688.
|
|
[25] KIM W, KHAN SK, GVOZDENOVIC-JEREMIC J, et al. Hippo signaling interactions with Wnt/β-catenin and Notch signaling repress liver tumorigenesis[J]. J Clin Invest, 2017,127(1):137-152.
|
|
[26] MOON H, CHO K, SHIN S, et al. High risk of hepatocellular carcinoma development in fibrotic liver:Role of the HippoYAP/TAZ signaling pathway[J]. Int J Mol Sci, 2019, 20(3):581-583.
|
|
[27] LIN TH, SHAO YY, CHAN SY, et al. High serum transforming growth factor-β1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenib[J]. Clin Cancer Res,2015, 21(16):3678-3684.
|
|
[28] FERRIGNO O, LALLEMAND F, VERRECCHIA F, et al. Yesassociated protein(YAP65)interacts with Smad7 and potentiates its inhibitory activity against TGF-beta/Smad signaling[J]. Oncogene, 2002, 21(32):4879-4884.
|
|
[29] LIU F, LAGARES D, CHOI KM, et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis[J]. Am J Physiol Lung Cel Mol Physiol, 2015, 308(4):L344-357.
|
|
[30] VARELAS X, SAMAVARCHI-TEHRANI P, NARIMATSU M, et al.The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-β-SMAD pathway[J]. Dev Cell,2010, 19(6):831-844.
|
|
[31] de LA COSTE A, ROMAGNOLO B, BILLUART P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas[J]. Proc Natl Acad Sci U S A, 1998, 95(15):8847-8851.
|
|
[32] BARTEL DP. MicroRNAs:Target recognition and regulatory functions[J]. Cell, 2009, 136(2):215-233.
|
|
[33] LIU AM, POON RT, LUK JM. MicroRNA-375 targets Hipposignaling effector YAP in liver cancer and inhibits tumor properties[J]. Biochem Biophys Res Commun, 2010, 394(3):623-627.
|
|
[34] HAN LL, YIN XR, ZHANG SQ. miR-103 promotes the metastasis and EMT of hepatocellular carcinoma by directly inhibiting LATS2[J]. Int J Oncol, 2018, 53(6):2433-2444.
|
|
[35] RUAN T, HE X, YU J, et al. MicroRNA-186 targets Yes-associated protein 1 to inhibit Hippo signaling and tumorigenesis in hepatocellular carcinoma[J]. Oncol Lett, 2016, 11(4):2941-2945.
|
|
[36] LIU P, ZHANG H, LIANG X, et al. HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma[J]. Oncotarget, 2015, 6(30):29048-29059.
|
|
[37] WU H, ZHANG W, WU Z, et al. miR-29c-3p regulates DNMT3B and LATS1 methylation to inhibit tumor progression in hepatocel ular carcinoma[J]. Cel Death Dis, 2019, 10(2):48.
|
|
[38] KUDO M, FINN RS, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:A randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126):1163-1173.
|
|
[39] CUI YL. Targeted therapy for hepatocellular carcinoma[J].Chin J Dig Surg, 2018, 17(5):445-451.(in Chinese）崔云龙．肝癌的靶向治疗[J]．中华消化外科杂志，2018, 17(5):445-451.
|
|
[40] GAO J, RONG Y, HUANG Y, et al. Cirrhotic stiffness affects the migration of hepatocellular carcinoma cells and induces sorafenib resistance through YAP[J]. J Cell Physiol, 2019,234(3):2639-2648.
|
DownLoad: